Eli Lilly and CompanyEli Lilly and CompanyEli Lilly and Company

Eli Lilly and Company

No trades
See on Supercharts

Key facts today


Eli Lilly's stock has exceeded $1,000, raising speculation about a possible split, as such moves often happen when shares surpass $500. The rise is driven by its weight-loss drug, Zepbound.
Eli Lilly plans to launch an oral obesity drug after receiving 'national priority' review vouchers from the FDA, potentially speeding up the approval process.
Eli Lilly's blood thinner Effient showed better results than AstraZeneca's Brilinta in preventing heart issues among 1,800 diabetic patients, with complication rates of 14.2% versus 16.6%.
Analyze the impactAnalyze the impact
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪766.92 B‬CHF
‪9.62 B‬CHF
‪40.91 B‬CHF
‪849.49 M‬
Beta (1Y)
0.57
Employees (FY)
‪47 K‬
Change (1Y)
‪+4 K‬ +9.30%
Revenue / Employee (1Y)
Net income / Employee (1Y)

About Eli Lilly and Company


CEO
David A. Ricks
Website
Headquarters
Indianapolis
Founded
1876
ISIN
US5324571083
FIGI
BBG00Z4HJVR2
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Check out other big names from the same industry as LLYZ.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
XS238628644
Eli Lilly and Company 1.625% 14-SEP-2043
Yield to maturity
5.76%
Maturity date
Sep 14, 2043
LLY4099975
Eli Lilly and Company 4.65% 15-JUN-2044
Yield to maturity
5.65%
Maturity date
Jun 15, 2044
LLY6153503
Eli Lilly and Company 5.65% 15-OCT-2065
Yield to maturity
5.57%
Maturity date
Oct 15, 2065
LLY5750032
Eli Lilly and Company 5.1% 09-FEB-2064
Yield to maturity
5.56%
Maturity date
Feb 9, 2064
LLY5871804
Eli Lilly and Company 5.2% 14-AUG-2064
Yield to maturity
5.54%
Maturity date
Aug 14, 2064
LLY6003397
Eli Lilly and Company 5.6% 12-FEB-2065
Yield to maturity
5.54%
Maturity date
Feb 12, 2065
LLY5547405
Eli Lilly and Company 4.95% 27-FEB-2063
Yield to maturity
5.54%
Maturity date
Feb 27, 2063
US532457BU1
Eli Lilly and Company 4.15% 15-MAR-2059
Yield to maturity
5.50%
Maturity date
Mar 15, 2059
LLY5871803
Eli Lilly and Company 5.05% 14-AUG-2054
Yield to maturity
5.47%
Maturity date
Aug 14, 2054
LLY6153502
Eli Lilly and Company 5.55% 15-OCT-2055
Yield to maturity
5.47%
Maturity date
Oct 15, 2055
LLY5750031
Eli Lilly and Company 5.0% 09-FEB-2054
Yield to maturity
5.46%
Maturity date
Feb 9, 2054

See all LLYZ bonds 

VTI
Vanguard Total Stock Market ETF
Weight
1.01%
Market value
‪20.45 B‬
USD
VOO
Vanguard S&P 500 ETF
Weight
1.06%
Market value
‪14.95 B‬
USD
IVV
iShares Core S&P 500 ETF
Weight
1.41%
Market value
‪10.06 B‬
USD
SPY
SPDR S&P 500 ETF
Weight
1.41%
Market value
‪9.77 B‬
USD
SPY
SPDR S&P 500 ETF Trust
Weight
1.41%
Market value
‪9.77 B‬
USD
VUG
Vanguard Growth ETF
Weight
1.99%
Market value
‪6.80 B‬
USD
XLV
Health Care Select Sector SPDR Fund
Weight
14.67%
Market value
‪5.72 B‬
USD
VIG
Vanguard Dividend Appreciation ETF
Weight
2.82%
Market value
‪3.26 B‬
USD
IWF
iShares Russell 1000 Growth ETF
Weight
2.62%
Market value
‪3.21 B‬
USD
QUAL
iShares MSCI USA Quality Factor ETF
Weight
4.47%
Market value
‪2.33 B‬
USD
0A3D
iShares Core S&P 500 UCITS ETF
Weight
1.41%
Market value
‪1.94 B‬
USD

Explore more ETFs 

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on TURQUOISE exchange Eli Lilly and Company stocks are traded under the ticker LLYZ.
We've gathered analysts' opinions on Eli Lilly and Company future price: according to them, LLYZ price has a max estimate of 1,189.63 CHF and a min estimate of 614.64 CHF. Watch LLYZ chart and read a more detailed Eli Lilly and Company stock forecast: see what analysts think of Eli Lilly and Company and suggest that you do with its stocks.
LLYZ reached its all-time high on Mar 1, 2024 with the price of 705 CHF, and its all-time low was 200 CHF and was reached on Jun 7, 2021. View more price dynamics on LLYZ chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track Eli Lilly and Company financials in yearly and quarterly reports right on TradingView.
Eli Lilly and Company is going to release the next earnings report on Feb 11, 2026. Keep track of upcoming events with our Earnings Calendar.
LLYZ earnings for the last quarter are 5.59 CHF per share, whereas the estimation was 4.53 CHF resulting in a 23.33% surprise. The estimated earnings for the next quarter are 5.61 CHF per share. See more details about Eli Lilly and Company earnings.
Eli Lilly and Company revenue for the last quarter amounts to ‪14.02 B‬ CHF, despite the estimated figure of ‪12.79 B‬ CHF. In the next quarter, revenue is expected to reach ‪13.94 B‬ CHF.
LLYZ net income for the last quarter is ‪4.45 B‬ CHF, while the quarter before that showed ‪4.49 B‬ CHF of net income which accounts for −0.99% change. Track more Eli Lilly and Company financial stats to get the full picture.
Yes, LLYZ dividends are paid quarterly. The last dividend per share was 1.19 CHF. As of today, Dividend Yield (TTM)% is 0.57%. Tracking Eli Lilly and Company dividends might help you take more informed decisions.
Eli Lilly and Company dividend yield was 0.67% in 2024, and payout ratio reached 44.39%. The year before the numbers were 0.78% and 77.91% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 15, 2025, the company has ‪47 K‬ employees. See our rating of the largest employees — is Eli Lilly and Company on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Eli Lilly and Company EBITDA is ‪22.53 B‬ CHF, and current EBITDA margin is 41.75%. See more stats in Eli Lilly and Company financial statements.
Like other stocks, LLYZ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Eli Lilly and Company stock right from TradingView charts — choose your broker and connect to your account.